09:57 AM EST - Avant Technologies Inc : Along with its partner, Ainnova Tech, Inc., a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced Ainnova’s acquisition of an exclusive license for 4 groundbreaking, AI-driven algorithms from one of Asia’s most respected and largest healthcare institutions. These solutions, validated across diverse geographies, ethnicities, and socioeconomic populations with data from over 2 million patients, will join Ainnova’s existing diabetic retinopathy and retinal disease detection solutions. The 4 algorithms include early detection for cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease, and chronic kidney disease. Avant Technologies Inc
shares O.AVAI are trading up $0.03 at $0.62.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=7822038388076087
